Dave made a good case to play the BIIB data next week. He is leaning bullish, which could make price explode past $400. his downside expectation is between $300 and.
The lack of news continues as well as a generally weak market. While it certainly was not strong yesterday (and to start today), it feels more like indifference than a.
While we are talking about small numbers and small difference, I would argue that it looks like large caps are finally starting to show some relative strength to SMID. I.
Yesterday July 11, 2018 the FDA FDA issues 6 new draft guidance documents for gene therapy, clinical development and manufacturing guidance. Human Gene Therapy for Rare Diseases – FDA Draft Guidance for.
So I stay away and the sector does well and now that I am back, let us see how it does. I apologize for any weakness that my return causes.
Sarepta Therapeutics (SRPT) is attempting to build the most meaningful precision genetic medicine company in the world, and has laid out its strategy to investors of exactly how it plans.
Apparently I am the problem with the sector. I miss one day and the sector moves higher and now that I am back it is back to going lower. I.
We still might be able to salvage a bullish view but it is getting pretty difficult. Clearly the breakout did not occur but we are still in higher highs and.
This will be an interesting day to see if the breakout will be confirmed as real or confirmed as false. We are back testing the previous levels of resistance and.
Intermittent Claudication or as called IC is a peripheral artery disease (PAD) caused by fatty deposits that accumulate in the arteries of the leg and reduce blood flow to exercising muscle.
Sector strength continued and is clearly outperforming the broader market. While we have seen this happen for a couple days before, this feels more like a real breakout. Ideally, we.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
You would think replacing a computer would be an easy job, it apparently requires different layers of people and so not everyone was on campus yesterday. So at some point.
Nothing new to start the week outside of a pretty weak market. I am not sure what the catalyst outside of an extended market but it looks again like the.
The sector had a decent day, although participation was not great. We seem to be on the verge of breaking higher (at least in the XBI) but it will be.
Nothing too exciting in terms of market action yesterday. There was some relatively outperformance of large caps versus small caps but that was mainly due to the gene therapy carnage..
I missed out on how the sector traded at the end of the week but it seems like the large caps had the slight edge over the SMID. We are.
PLURISTEM (PSTI) a cell therapy company, developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions, company I’m following for years. Pluristem trading under.
The sector did a little better yesterday but given the strength of the market, it is not a great performance. That being said another couple days in the green and.
Despite the lack of any real thesis changing news, ASCO seemed to be fairly typical. There will be a couple of big winners but more losers as you have both.
Some interesting news as we head into ASCO. While the trading action is a little better for the sector it is not exactly tearing it up. Of course, the lack.